Joseph A Reddy Selected Research

EC145

12/2018	Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic.
1/2016	High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide.
10/2014	The folate receptor as a rational therapeutic target for personalized cancer treatment.
4/2014	Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
3/2014	Folate-vinca alkaloid conjugates for cancer therapy: a structure-activity relationship.
2/2011	Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications.
9/2009	In vivo structural activity and optimization studies of folate-tubulysin conjugates.
10/2007	Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145.
5/2007	Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joseph A Reddy Research Topics

Disease

29	Neoplasms (Cancer) 01/2020 - 06/2002
3	Weight Loss (Weight Reduction) 01/2019 - 05/2007
2	Lung Neoplasms (Lung Cancer) 01/2016 - 10/2014
1	Polycystic Kidney Diseases (Polycystic Kidney Disease) 01/2019
1	Prostatic Neoplasms (Prostate Cancer) 01/2019
1	Ovarian Neoplasms (Ovarian Cancer) 10/2014
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2014
1	Carcinoma (Carcinomatosis) 01/2013
1	Neutropenia 01/2013
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2013
1	Neoplasm Metastasis (Metastasis) 01/2013
1	Constipation 02/2011
1	Body Weight (Weight, Body) 04/2010
1	Lymphoma (Lymphomas) 05/2007

Drug/Important Bio-Agent (IBA)

24	Folic Acid (Vitamin M)FDA LinkGeneric 01/2019 - 06/2002
12	Pharmaceutical PreparationsIBA 01/2020 - 04/2004
9	EC145IBA 12/2018 - 05/2007
5	tubulysin BIBA 01/2019 - 12/2008
5	AlkaloidsIBA 12/2018 - 02/2011
4	Biological ProductsIBA 01/2019 - 07/2005
3	EC0305IBA 06/2017 - 12/2008
3	HydrazinesIBA 04/2016 - 10/2014
3	LigandsIBA 12/2008 - 12/2006
2	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 06/2002
2	Biomarkers (Surrogate Marker)IBA 01/2019 - 10/2014
2	AntigensIBA 01/2019 - 04/2004
2	Paclitaxel (Taxol)FDA LinkGeneric 12/2018 - 08/2006
2	HydrazonesIBA 04/2016 - 08/2006
2	Folic Acid AntagonistsIBA 10/2014 - 04/2010
2	Mitomycin (Mitomycin-C)FDA LinkGeneric 08/2006 - 07/2005
1	Docetaxel (Taxotere)FDA Link 01/2019
1	Cisplatin (Platino)FDA LinkGeneric 12/2018
1	EC0531IBA 06/2017
1	Mannitol (Osmitrol)FDA LinkGeneric 04/2016
1	BuffersIBA 04/2016
1	Antineoplastic Agents (Antineoplastics)IBA 04/2016
1	Acetic Acid (Vinegar)FDA LinkGeneric 04/2016
1	Alanine (L-Alanine)FDA Link 04/2016
1	AcetoneIBA 04/2016
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2016
1	PlatinumIBA 10/2014
1	EC0905IBA 01/2013
1	EC 0489IBA 02/2011
1	Pemetrexed (MTA)FDA Link 04/2010
1	CB 3717IBA 04/2010
1	EC0225IBA 09/2007
1	Therapeutic UsesIBA 07/2007
1	HaptensIBA 12/2006
1	Fluorescein-5-isothiocyanate (FITC)IBA 12/2006
1	AntibodiesIBA 12/2006
1	Blocking AntibodiesIBA 12/2006
1	Neoplasm Antigens (Tumor Antigens)IBA 12/2006
1	AmidesIBA 08/2006
1	DisulfidesIBA 08/2006
1	AcidsIBA 08/2006
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 06/2002
1	LipidsIBA 06/2002

Therapy/Procedure

12	Therapeutics 01/2019 - 12/2004
1	Immunotherapy 12/2006
1	Duration of Therapy 12/2006
1	Drug Therapy (Chemotherapy) 08/2006
1	Intravenous Administration 06/2002